Literature DB >> 17498121

Rodent models of streptozotocin-induced diabetic nephropathy.

Greg H Tesch1, Terri J Allen.   

Abstract

Streptozotocin-induced pancreatic injury is commonly used for creating rodent models of type 1 diabetes which develop renal injury with similarities to human diabetic nephropathy. This model can be established in genetically modified rodents for investigating the role of molecular mechanisms and genetic susceptibility in the development of diabetic nephropathy. In this report, the authors describe and compare the current protocols being used to establish models of diabetic nephropathy in rat and mouse strains using streptozotocin. The authors also list some of the histological criteria and biochemical measurements which are being used to validate these models. In addition, our review explains some of the key aspects involved in these models, including the impact of streptozotocin-dosage, uninephrectomy, hypertension and genetically modified strains, which can each affect the development of disease and the interpretation of findings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498121     DOI: 10.1111/j.1440-1797.2007.00796.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  148 in total

1.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 2.  Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.

Authors:  Pradip K Kamat; Anuradha Kalani; Shivika Rai; Santosh Kumar Tota; Ashok Kumar; Abdullah S Ahmad
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

3.  mTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice.

Authors:  Shan Wang; Shan-lei Zhou; Fang-yuan Min; Jin-ju Ma; Xia-jie Shi; Erika Bereczki; Jing Wu
Journal:  Metab Brain Dis       Date:  2014-03-30       Impact factor: 3.584

4.  Animal models of regression/progression of kidney disease.

Authors:  Beom Jin Lim; Hai-Chun Yang; Agnes B Fogo
Journal:  Drug Discov Today Dis Models       Date:  2014

5.  Long-term intranasal insulin administration improves spatial memory in male rats with prolonged type 1 diabetes mellitus and in healthy rats.

Authors:  I B Sukhov; V N Shipilov; O V Chistyakova; A M Trost; A O Shpakov
Journal:  Dokl Biol Sci       Date:  2014-01-03

Review 6.  Chronic Wound Biofilm Model.

Authors:  Kasturi Ganesh; Mithun Sinha; Shomita S Mathew-Steiner; Amitava Das; Sashwati Roy; Chandan K Sen
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-07-01       Impact factor: 4.730

Review 7.  Heme Oxygenase-1 in Kidney Health and Disease.

Authors:  Jeremie M Lever; Ravindra Boddu; James F George; Anupam Agarwal
Journal:  Antioxid Redox Signal       Date:  2016-05-26       Impact factor: 8.401

8.  Effect of streptozotocin-induced diabetes on performance on a progressive ratio schedule.

Authors:  Lourdes Valencia-Torres; C M Bradshaw; Arturo Bouzas; Enrique Hong; Vladimir Orduña
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

9.  PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease.

Authors:  Yajuan Li; Qingsong Hu; Chunlai Li; Ke Liang; Yu Xiang; Heidi Hsiao; Tina K Nguyen; Peter K Park; Sergey D Egranov; Chandrashekar R Ambati; Nagireddy Putluri; David H Hawke; Leng Han; Mien-Chie Hung; Farhad R Danesh; Liuqing Yang; Chunru Lin
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

Review 10.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.